Roger Li, MD
Urology · Loma Linda, CANPI 1841515525
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $52,450 of the $63,252 with a category attached, or 82.9%. It is spread thinly across 15 manufacturers, the largest accounting for just 17.4%. 2025 is the largest year on record at $30,355, 2.7 times the $11,079 reported in 2019. Among urology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 71 payments — averaging $890.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$11K
- E.r. Squibb & Sons, L.L.C.$8K
- Urogen Pharma, Inc.$7K
- Janssen Global Services, LLC$7K
- Pfizer$7K
- Merck$7K
- plus $17K from 9 others
Across 136 payments — averaging $16,670 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.4M
- Janssen Research & Development, LLC$916K
- Pfizer$780
- E.r. Squibb & Sons, L.L.C.$679
What the payments were for
- Consulting fees$52,45083%
- Speaking & faculty fees$5,3008%
- Travel & lodging$3,6146%
- Food & beverage$1,8813%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 8 | $11,001 |
| E.r. Squibb & Sons, L.L.C. | 9 | $8,488 |
| Urogen Pharma, Inc. | 2 | $6,900 |
| Janssen Global Services, LLC | 9 | $6,894 |
| Pfizer | 8 | $6,844 |
| Merck | 14 | $6,541 |
| AstraZeneca | 4 | $4,923 |
| Janssen Scientific Affairs, LLC | 8 | $3,714 |
| Astellas Pharma US Inc | 2 | $2,460 |
| Photocure Inc | 1 | $2,250 |
| Astellas Pharma Global Development | 2 | $2,048 |
| Janssen Research & Development, LLC | 1 | $1,013 |
| Astrazeneca UK Limited | 1 | $117 |
| Johnson & Johnson | 1 | $39 |
| BD | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,252 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxybutynin Chloride | 52 | $495 |
| Tamsulosin Hcl | 13 | $180 |
Paid to pharmacies, not to this prescriber.
Other urology in Loma Linda
- Stephen FreedlandWest Hollywood$1.9M
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Steven WilsonIndio$1.1M
- Stuart HoldenLos Angeles$1.1M
- Elward CrawfordSan Diego$849K
- Edward UchioOrange$849K
- Victor ChingUpland$809K
- Jaime LandmanOrange$657K
- William AronsonLos Angeles$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.